Methods of inhibiting bone resorption
AssigneeMerck & Co., Inc.
InventorsJohn E. Fisher, Gideon A. Rodan
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of inhibiting bone resorption comprising administering a therapeutically effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Claims25
A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.
A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.
A pharmaceutical composition comprising a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormone.
A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.
A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.
Dependencies are inferred from the claim text.